E-resources
PDF-
Kohno, Takashi; Ichikawa, Hitoshi; Totoki, Yasushi; Yasuda, Kazuki; Hiramoto, Masaki; Nammo, Takao; Sakamoto, Hiromi; Tsuta, Koji; Furuta, Koh; Shimada, Yoko; Iwakawa, Reika; Ogiwara, Hideaki; Oike, Takahiro; Enari, Masato; Schetter, Aaron J; Okayama, Hirokazu; Haugen, Aage; Skaug, Vidar; Chiku, Suenori; Yamanaka, Itaru; Arai, Yasuhito; Watanabe, Shun-Ichi; Sekine, Ikuo; Ogawa, Seishi; Harris, Curtis C; Tsuda, Hitoshi; Yoshida, Teruhiko; Yokota, Jun; Shibata, Tatsuhiro
Nature medicine, 03/2012, Volume: 18, Issue: 3Journal Article
We identified in-frame fusion transcripts of KIF5B (the kinesin family 5B gene) and the RET oncogene, which are present in 1-2% of lung adenocarcinomas (LADCs) from people from Japan and the United States, using whole-transcriptome sequencing. The KIF5B-RET fusion leads to aberrant activation of RET kinase and is considered to be a new driver mutation of LADC because it segregates from mutations or fusions in EGFR, KRAS, HER2 and ALK, and a RET tyrosine kinase inhibitor, vandetanib, suppresses the fusion-induced anchorage-independent growth activity of NIH3T3 cells.
